0000950170-23-063925.txt : 20231114
0000950170-23-063925.hdr.sgml : 20231114
20231114192251
ACCESSION NUMBER: 0000950170-23-063925
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231110
FILED AS OF DATE: 20231114
DATE AS OF CHANGE: 20231114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Awad Antoine
CENTRAL INDEX KEY: 0001820122
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37566
FILM NUMBER: 231408620
MAIL ADDRESS:
STREET 1: C/O SYNLOGIC, INC.
STREET 2: 301 BINNEY STREET, SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNLOGIC, INC.
CENTRAL INDEX KEY: 0001527599
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261824804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-401-9975
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Mirna Therapeutics, Inc.
DATE OF NAME CHANGE: 20110809
4
1
ownership.xml
4
X0508
4
2023-11-10
0001527599
SYNLOGIC, INC.
SYBX
0001820122
Awad Antoine
C/O SYNLOGIC, INC.
301 BINNEY STREET, SUITE 402
CAMBRIDGE
MA
02142
true
Chief Operating Officer
false
Stock Option (right to buy)
130.35
2023-11-10
4
D
false
3666
D
2029-02-28
Common Stock
3666
0
D
Stock Option (right to buy)
128.85
2023-11-10
4
D
false
666
D
2029-03-05
Common Stock
666
0
D
Stock Option (right to buy)
9.30
2023-11-10
4
D
false
6666
D
2033-03-16
Common Stock
6666
0
D
Stock Option (right to buy)
25.50
2023-11-10
4
D
false
4666
D
2030-03-10
Common Stock
4666
0
D
Stock Option (right to buy)
27.75
2023-11-10
4
D
false
4666
D
2030-07-14
Common Stock
4666
0
D
Stock Option (right to buy)
52.50
2023-11-10
4
D
false
4666
D
2031-03-10
Common Stock
4666
0
D
Stock Option (right to buy)
29.25
2023-11-10
4
D
false
11031
D
2032-02-04
Common Stock
11031
0
D
Stock Option (right to buy)
9.30
2023-11-10
4
D
false
16666
D
2033-03-16
Common Stock
16666
0
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
3666
A
2029-02-28
Common Stock
3666
3666
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
666
A
2029-03-05
Common Stock
666
666
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
6666
A
2033-03-16
Common Stock
6666
6666
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
4666
A
2030-03-10
Common Stock
4666
4666
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
4666
A
2030-07-14
Common Stock
4666
4666
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
4666
A
2031-03-10
Common Stock
4666
4666
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
11031
A
2032-02-04
Common Stock
11031
11031
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
16666
A
2033-03-16
Common Stock
16666
16666
D
In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
The shares subject to this option are fully vested as of the date hereof.
These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
The shares subject to this option vest in approximately equal monthly installments beginning on July 1, 2020 through July 1, 2024.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
/s/ Antoine Awad
2023-11-14